Patents by Inventor Rajendra V. Deshpande
Rajendra V. Deshpande has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190370259Abstract: Systems, devices, and methods for executing workflow instances (310,410) of management of continuously changing data and queries. In one embodiment, a computing device may be configured to determine a set of related structured data comprising a key and associated value (330), where an associated ID and name for each related structured data of the set of related structured data may be determined (340). Additionally, a unique ID may be determined based on the determined associated ID and name (340). A match may then be determined for the set of core data elements based on a received message (350) and an ordered list of results retrieved based on at least one of: the matched ID, the matched name, and the matched ID and name (360).Type: ApplicationFiled: January 12, 2017Publication date: December 5, 2019Inventor: Rajendra V. Deshpande
-
Patent number: 10042957Abstract: Systems, devices, and methods for executing workflow instances of management of continuously changing data and queries. In one embodiment, a computing device may be configured to determine a set of related structured data comprising a key and associated value, where an associated ID and name for each related structured data of the set of related structured data may be determined. Additionally, a unique ID may be determined based on the determined associated ID and name. A match may then be determined for the set of core data elements based on a received message and an ordered list of results retrieved based on at least one of: the matched ID, the matched name, and the matched ID and name.Type: GrantFiled: January 12, 2017Date of Patent: August 7, 2018Assignee: INNOVATIONDOCK, INC.Inventor: Rajendra V. Deshpande
-
Patent number: 10035861Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: November 24, 2014Date of Patent: July 31, 2018Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20180196886Abstract: Systems, devices, and methods for executing workflow instances of management of continuously changing data and queries. In one embodiment, a computing device may be configured to determine a set of related structured data comprising a key and associated value, where an associated ID and name for each related structured data of the set of related structured data may be determined. Additionally, a unique ID may be determined based on the determined associated ID and name. A match may then be determined for the set of core data elements based on a received message and an ordered list of results retrieved based on at least one of: the matched ID, the matched name, and the matched ID and name.Type: ApplicationFiled: January 12, 2017Publication date: July 12, 2018Inventor: Rajendra V. Deshpande
-
Publication number: 20150310017Abstract: A method, system and program comprise submitting an innovation summary to a server unit to be processed by an editorial review system. An acceptance of the innovation summary by the editorial review system posts the innovation summary. An innovation solicitation summary is submitted to the server unit to be processed by the editorial review system. An acceptance of the innovation solicitation summary by the editorial review system posts the innovation solicitation summary. Results of a search/match process of posted innovation summaries and posted innovation solicitation summaries are received. The search/match process at least utilizes a matching algorithm that uses defined innovation attributes, tags, text strings, and boost factors. A communication of an interest in a match in the received results is sent.Type: ApplicationFiled: April 29, 2014Publication date: October 29, 2015Inventor: Rajendra V. Deshpande
-
Publication number: 20150274829Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: November 24, 2014Publication date: October 1, 2015Inventors: Frank J. CALZONE, Rajendra V. DESHPANDE, Mei-Mei TSAI
-
Patent number: 8895008Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20140147444Abstract: Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: ApplicationFiled: March 14, 2013Publication date: May 29, 2014Applicant: AMGEN INC.Inventors: Rajendra V. DESHPANDE, William J. BOYLE, John K. SULLIVAN, Anna Hitz
-
Publication number: 20130236457Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: May 10, 2013Publication date: September 12, 2013Applicant: Amgen Inc.Inventors: Frank J. CALZONE, Rajendra V. DESHPANDE, Mei-Mei TSAI
-
Patent number: 8460662Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: March 28, 2012Date of Patent: June 11, 2013Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20120237516Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: March 28, 2012Publication date: September 20, 2012Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 8168409Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: November 24, 2010Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20110070615Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 7871611Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: December 20, 2005Date of Patent: January 18, 2011Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20090285824Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: December 20, 2005Publication date: November 19, 2009Applicant: AMGEN INC.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 7084257Abstract: Selective binding agents of interferon-gamma (IFN?) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN? and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: GrantFiled: October 5, 2001Date of Patent: August 1, 2006Assignee: Amgen Inc.Inventors: Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20030103978Abstract: Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: ApplicationFiled: February 22, 2001Publication date: June 5, 2003Applicant: Amgen Inc.Inventors: Rajendra V. Deshpande, Anna Hitz, William James Boyle, John K. Sullivan
-
Publication number: 20030099647Abstract: Selective binding agents of interferon-gamma (IFN&ggr;) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN&ggr; and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: ApplicationFiled: October 5, 2001Publication date: May 29, 2003Inventors: Rajendra V. Deshpande, Mei-Mei Tsai